Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Exclusion Criteria

• •Patients with allergy or contraindication to the study drug;
• •Female patients who are pregnant or breast-feeding.
• •Patients with active infection
• •Patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment;
• •Patients with mental illness or other states unable to comply with the protocol;
• •Less than 6 weeks after surgical operation of important organs.
• •Liver function: ALT and AST\>2.5 times the upper limit of normal ,bilirubin\>2 times the upper limit of normal;Renal function: creatinine \>the upper limit of normal;
• •The patient is not suitable for this clinical trial (poor compliance, substance abuse, etc.)